• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Drugs Acting on Colon and Rectum
    31 Drugs classified under this therapeutic system

    All the Therapeutic System Drugs

    Filter by letter: ALL A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
    partial basket chart

    Advanced Therapy. Darvadstrocel 30 million cells/vial.
    VIAL (suspens. for inj): 1×30 million cells. A single dose of Alofisel consists of 120 million cells supplied. in 4 vial. Each vial contains 30 million cells in 6 mL of susp. The full content of the 4 vial. must be admin. for the tmt. of up to two intern. openings and up to three exter. openings. This means that with a dose of 120 million cells it is possible to treat up to three fistula tracts that open to the perianal area. The efficacy or safety of repeat admin. of this drug has not been established.
    Tmt. of complex perianal fistulas in adult pts. with non-active/mildly active luminal Crohn’s dis., when fistulas have shown an inadeq. response to at least one convention. or biologic ther. The durg should be used only after conditioning of the fistulas.
    C/I: Hypersens. to the active subst. or to excipients or to bovine serum.

    not in the basket chart

    TNF Blocking Agent. Adalimumab 50 mg/ml..
    PRE-FILLED SYRINGE: 2 ×(20 mg/0.4 mL, 40mg/0.8ml)
    PRE-FILLED PEN: 2× (40mg /0.8 ml).
    Dosage ajust. individ. accord. to pt. med. condit.
    RA: in comb. with methotrexate-tmt. of moder.-sev., active RA in adult pts. when the response to dis.-modif. anti-rheumat.drugs includ. methotrexate has been inadequate.
    The tmt. of sev., active and progres. RA  in adult.not previous. treated with methotrexate,  given as monother. in case of intolerance to methotrexate or when continued tmt. with methotrexate is inappropr. AMGEVITA has been shown to reduce the rate of progress. of joint damage as measured by X-ray and to improve physical funct., when given in comb. with methotrexate.
    Axial spondyloarthritis Ankylosing spond. (AS): tmt. of adult. with severe active AS who have had an inadeq. response to convent. ther.
    Axial spondyloarthritis without radiograph. evidence of AS: tmt. of adults with sev. axial spondyloarthritis without radiograph.evidence of AS, but with object. signs of inflamm. by radiolog. and/or lab. tests includ. MRI and serum CRP levels, who have had an inadequate response to, or are intoler, to,NSAID’s.
    Psoriatic arthritis: tmt. of active and progress. psoriat. arthritis in adults when the response to previous dis.-modif. anti-rheum.drug ther. has been inadequate. Adalimumab has been shown to reduce the rate of progress. of peripher. joint damage as measured by X-ray in pts. with polyarticular symmetr. subtypes of the dis. and to improve physic. func.
    Psoriasis: tmt. of moder.-sev. chron. plaque psoriasis in adult pts. who are candidates for system. ther.
    Hidradenitis suppurativa (HS): tmt. of active moder.- sev. hidradenitis suppurativa (acne inversa) in adult pts. with an inadequate response to convent. system. HS ther.
    Crohn’s dis. : reducing signs and sympt.and induc.and maintain. clinical remiss. in adult pts. with moder.- sev. active Crohn’s dis. who have had an inadequate response to convent. ther. AMGEVITA is indic. for reduc. signs and sympt. and induc. clinical remiss. in these pts. if they have also lost response to or are intoler. to infliximab.
    Ulcerat. colit.: tmt. of moder.-sev. active ulcerat. colit. in adult pts. who have had an inadequate response to convent. ther. includ. corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intoler. to or have med. contraindicat. for such therapies.
    Uveitis : tmt. of non-infect. intermed., posterior and panuveitis in adult pts. who have had an inadequate response to corticosteroids, in pts. in need of corticosteroid-sparing, or in whom corticosteroid tmt. is inappropr.
    Intestinal Behcet's dis.:  tmt. of intestin. Behcet’s dis. in pts. who have had an inadequate response to convention. ther.

    C/I: Hypersens.
    Active tuberculosis or other sev. infect. such as sepsis, and opportunist.infec.
    Moder.-sev. HF(NYHA class III/IV).

    not in the basket chart
    Multiple ingredients

    CCB, Local Anesthetic. Lidocaine HCl 1.5%, Nifedipine 0.3%.
    RECTAL CR.: 30g. Should be applied twice dly. for at least 3 wks. See lit.
    Tmt. of anal fissures and proctolog.  general. associate. with anal sphincter hypertonia.
    C/I: Hypersens.  to the active ingred., partic.  to Lidocaine (& other local anesthet.  with a similar amidic type structure). Presumed or ascertained  preg. & lact.

    Tradis Gat
    full basket chart

    5-Aminosalicylic Acid Derivative. Mesalazine 400 mg, 800 mg.
    TABS: 100 x 400 mg. 3-6 tabs. dly. in div.
    doses bef. meals.
    TABS: 60 x 800 mg. Ulc. colit: Maint.
    remission: 1.2-2.4 g dly in div. doses
    bef. meals. Chron’s dis: 2.4 g dly in div.
    doses bef. meals. Child: No specif.
    Maint. remission in ulcerat. colit., acute
    episodes Crohn’s dis.
    Ulcerat. proctit.
    C/I: Hypersens. to salicylates, liver and
    kidney funct. disords., gastric or duod.
    ulc., pregn., lact., diabetes.

    Axiban Sublingual Drops IMC-Medical Grade Cannabis Oil
    not in the basket chart
    Multiple ingredients
    Axiban Sublingual Drops IMC-Medical Grade Cannabis Oil

    Cannabinoids. THC 0.3, 0.9, 1.5, 3, 4.5, 6 mg/drop, CBD 0.6, 0.9, 1.2, 3, 4.5, 6 mg/drop.
    *This product requires a license for medical cannabis.
    BOTTLE. (sublingual drop.): 10gr (330 drops). Dosage should be adjust. individual.
    The Israel MOH has outlined in Guidance 106 the 12 indicat. for which med. cannabis is indicated. Accord. to this guidance, the 11 indicat. for this product are:
    Chemother-induc. nausea and vomit. (CINV)/ chemother induc. pain.
    Metastat. cancer pain.
    Neuropath. pain.
    Spastic. of MS.
    Pain in Parkinson's dis.
    Cachexia in AIDS.
    Tourette's syndr.
    Recalcitrant epilep. in adult. (Note: Accord. to Guidance 106, med. cannab. is also indic. for recalcitrant epilep. in ped. pts. but this is not an indicat. for this product)
    Palliative care for termin. ill pts.
    Post- traum. stress disord.
    In general, the use of med. cannabis is indicated in pts. who have adequate. tried and failed convent. ther.
    Please refer to Guidance 106 for details.
    In addition, for an individ. pt. with a clinical. signific. med. condit. that cannot be adequate. managed by convent. ther. and which is not includ. as one of the 12 approved indicat. (eg autism, fibromyalgia), the physician can appeal to the MOH Committee for Med. Cannabis to ask for approval on an individ. exception. basis.
    C/I: Prior, current/ family history (1st degr. relative) of psychos. or schizophr. or schizoaffective disord., a hist. of addict. or substance abuse (include. cannabis use disord.or addict. to alcohol), use in preg.or lact., use in pts. <18 yrs. old, bipol.disord., hypersens. to cannabis, coconut oil, palm kernel oil.
    In pts. with hepat. cancer, it is recommend. not to use med. cannab. that contains THC.
    See lit.

    partial basket chart

    Corticosteroid. Budesonide 3 mg.
    Gastro-Resist. CAPS: 100. Swallow with
    glass of water about 1/2 hr bef. meals:
    Crohns: 9mg/d: 3 caps in morning or 1
    cap X 3/d. Collag. colitis: 9mg/d: 3 caps
    once dly in the morning. Autoimm.
    hepat.: Induct. of remiss.: 1 cap X 3/d.
    Maint. of remiss.: 1 cap X 2/d.
    Acute mild - moderate Crohn’s dis. with
    involv. of the ileum (twisted intest.) and/
    or ascend. colon (part of large bowel).
    Collagenous colitis. Autoimmune
    C/I: Hypersens., hepatic cirrhosis.

    Other therapeutic systems under Alimentary System